Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: A systematic review and meta-analysis

Annals of Hematology

Volumn 93, Issue 8, 2014, Pages 1279-1286

  Port, M ^a   Bottcher M ^a   Thol, F ^a   Ganser, A ^a   Schlenk, R ^b   Wasem, J ^c   Neumann, A ^c   Pouryamout, L ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Acute myeloid leukemia; Meta analysis; Mutated nucleophosmin; Mutations of fms related tyrosine kinase 3; Mutations of the CEBPA gene; Normal karyotype

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; FLT3 LIGAND; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PROGNOSIS; GENE DUPLICATION; GENE MUTATION; HAZARD RATIO; HUMAN; KARYOTYPE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW;

ADULT; AGE FACTORS; CCAAT-ENHANCER-BINDING PROTEINS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904760463     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2072-6     Document Type: Review

References (32)

1. Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acutemyeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474. doi:10.1182/blood-2009-07-235358
2. Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365. doi:10.1182/blood-2009-11-254441
3. Marcucci G, Haferlach T, Dohner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29:475-486. doi:10.1200/JCO.2010.30.2554
4. Schlenk RF, Döhner K, Krauter JJ et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918. doi:10.1056/NEJMoa074306
5. Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937-951. doi:10.1182/blood-2009-03-209262
6. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700-b2700. doi:10.1136/bmj.b2700
7. Higgins J, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. doi: Available from www.cochrane-handbook.org.
8. Boissel N, Renneville A, Biggio V et al (2005) Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 106:3618-3620. doi:10.1182/blood-2005-05-2174
9. Damm F, Heuser M, Morgan M et al (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561-4568. doi:10.1182/blood-2010-08-303479
10. Damm F, Heuser M, Morgan M et al (2010) Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 28:578-585. doi:10.1200/JCO.2009.23.0342
11. Dohner K, Schlenk RF, Habdank M et al (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106:3740-3746. doi:10. 1182/blood-2005-05-2164
12. Dunna NR, Rajappa S, Digumarti R et al (2010) Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML). Asian Pac J Cancer Prev 11:1811-1816
13. Fröhling S, Schlenk RF, Stolze I et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633. doi:10.1200/JCO.2004.06.060
14. Gale RE, Green C, Allen C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776-2784
15. Heuser M, Beutel G, Krauter J et al (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108:3898-3905. doi:10.1182/blood-2006-04-014845
16. Kim YK, Kim HJN, Lee SR et al (2010) Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol 45:36-45. doi:10.5045/kjh.2010.45.1.36
17. Langer C, Marcucci G, Holland KB et al (2009) Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 27:3198-3204. doi:10.1200/JCO.2008.20.6110
18. Langer C, Radmacher MD, Ruppert AS et al (2008) High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st. Blood 111:5371-5379. doi:10.1182/blood-2007-11-124958
19. Marcucci G, Maharry K, Radmacher MD et al (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 26:5078 -5087. doi:10. 1200/JCO.2008.17.5554
20. Paschka P, Marcucci G, Ruppert AS et al (2008) Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26:4595-4602. doi:10.1200/JCO.2007.15.2058
21. Taskesen E, Bullinger L, Corbacioglu A, et al. (2011) Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117:2469-2475. doi:10.1182/blood-2010-09-307280
22. Thiede C, Koch S, Creutzig E et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011-4020. doi:10.1182/blood-2005- 08-3167
23. Virappane P, Gale R, Hills R et al (2008) Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26:5429 - 5435. doi:10.1200/JCO. 2008.16.0333
24. Wagner K, Damm F, Goehring G et al (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28:2356-2364. doi:10.1200/JCO.2009.27.6899
25. Whitman SP, Ruppert AS, Radmacher MD et al (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111:1552-1559. doi:10.1182/blood-2007-08-107946
26. Arber DA, Brunning RD, Le Beau MM et al (2008) Acute myeloid leukaemia and related precursor neoplasms. In: Swerdlow SH, Campo E, Harris NL (eds) WHO Classif. Tumours Haematop. Lymphoid Tissues, 4th edn. IARC Press, Lyon, pp 109-166
27. Yanada M, Matsuo K, Suzuki T et al (2005) Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leuk Off J Leuk Soc Am Leuk Res Fund UK 19:1345-1349. doi:10.1038/sj.leu.2403838
28. Thol F, Damm F, Lüdeking A et al (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29:2889-2896. doi:10.1200/JCO.2011.35.4894
29. Thol F, Damm F, Wagner K et al (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116:614-616. doi:10.1182/blood-2010-03-272146
30. Schnittger S, Schoch C, Kern W et al (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acutemyelogenous leukemia with a normal karyotype. Blood 106:3733-3739. doi:10. 1182/blood-2005-06-2248
31. Schlenk RF, Taskesen E, van Norden Y et al (2013) The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 122:1576-1582. doi:10.1182/blood-2013-05-503847
32. Schneider F, Hoster E, Schneider S et al (2012) Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol 91:9-18. doi: 10.1007/s00277-011-1280-6